ArticleDiabetes & metabolism journal2021

Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea.

Kyuho Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.